NewsJanuary 5
Ascensia Diabetes Care Signs Definitive Agreement to Transfer Eversense® CGM Commercialization to Senseonics — Agreement with Senseonics integrates Eversense manufacturing and commercial activities to accelerate growth
Tokyo, Japan – January 5 2026 – PHC Holdings Corporation (President, Representative Director and CEO: Kyoko Deguchi, TSE: 6523) and its subsidiary Ascensia Diabetes Care, a global diabetes care company, announced that Ascensia has signed a definitive agreement to transfer the commercial operations for Eversense® Continuous Glucose Monitoring (CGM) systems to Eversense maker Senseonics Holdings, Inc. (NASDAQ: SENS), formalizing a memorandum of understanding MOU the companies signed in September. The transfer of CGM U.S. business asset united Eversense R&D, manufacturing, and commercial activities within Senseonics beginning January 1, 2026 and for CGM European business, agreements in each country are expected to be executed within January and the transfers are expected to be completed on or before June 30, 2026.
Under its collaboration with Senseonics, Ascensia acquired exclusive global distribution rights for Eversense in 2020 and launched Eversense 365, the world’s first and only one-year CGM system, in the U.S. in October 2024. Under this new agreement, most of the Eversense commercial team at Ascensia including Brian Hansen, President of CGM, has transitioned to Senseonics.
PHC Holdings Corporation and Ascensia are provide Transition Service Agreements as needed while Senseonics establishes its global infrastructure. The companies anticipate minimal disruption for business partners, patients and providers.
Koichiro Sato, Chief Operating Officer and Chief Strategy Officer of PHC Holdings Corporation and CEO of Ascensia, commented: “We are very proud to have worked with Senseonics on commercializing Eversense and we are committed to supporting Senseonics in establishing their own commercial operations and smoothly transitioning to them.”
Tim Goodnow, President and Chief Executive Officer of Senseonics, commented: “We truly appreciate the partnership and investment that PHC Group and Ascensia made in Senseonics, and we are pleased to welcome the talented commercial team and continue to build momentum for Eversense 365.”
For financial information about PHC Holdings Corporation please visit: https://www.phchd.com/global/ir
About PHC Holdings Corporation
PHC Holdings Corporation (TSE 6523) is a global collection of healthcare companies with a mission of contributing to the health of society through healthcare solutions that have a positive impact and improve the lives of people. Its subsidiaries (referred to collectively as PHC Group) include PHC Corporation, Ascensia Diabetes Care, Epredia, LSI Medience Corporation, Wemex Corporation and Mediford Corporation. Together, these companies develop, manufacture, sell and service solutions across diabetes management, healthcare solutions, life sciences and diagnostics. PHC Group’s consolidated net sales in FY2024 were JPY 361.6 billion with global distribution of products and services in more than 125 countries and regions.
www.phchd.com
About Ascensia Diabetes Care
Ascensia Diabetes Care is a global company focused entirely on helping people with diabetes. Our mission is to empower those living with diabetes through innovative solutions that simplify and improve their lives.
We are home to the world-renowned CONTOUR® portfolio of blood glucose monitoring systems. Our products combine advanced technology with user-friendly functionality to help people with diabetes manage their condition and make a positive difference to their lives. As a trusted partner in the diabetes community, we collaborate closely with healthcare professionals and other partners to ensure our products meet the highest standards of accuracy, precision and reliability, and that we conduct our business compliantly and with integrity.
Ascensia is a member of PHC Group and was established in 2016 through the acquisition of Bayer Diabetes Care by PHC Holdings Corporation. Ascensia products are sold in more than 100 countries. Ascensia has direct commercial organizations in 29 countries.
For further information, please visit the Ascensia Diabetes Care website at http://www.ascensia.com.